ライフサイエンスコーパス: persistent pulmonary hypertension

1 g adjunct to inhaled NO for the treatment of persistent pulmonary hypertension.

2 e decreases severe hypoxemia in infants with persistent pulmonary hypertension.

3 of BMPR2 in SMC, decreasing ARRB2 prevented persistent pulmonary hypertension.

4 ecific deletion of Bmpr2 (EC-Bmpr2(-/-)) and persistent pulmonary hypertension.

5 ate or severe right ventricular hypokinesis, persistent pulmonary hypertension, a patent foramen oval

6 oembolic pulmonary hypertension (CTEPH), but persistent pulmonary hypertension after PTE, as a result

7 tion-based cohort study examines the risk of persistent pulmonary hypertension among newborns in Denm

8 mproves systemic oxygenation in infants with persistent pulmonary hypertension and may reduce the nee

9 ysis may identify CTEPH patients at risk for persistent pulmonary hypertension and poor outcome after

10 ed to the underlying disease associated with persistent pulmonary hypertension and that lung recruitm

11 borns with hypoxemic respiratory failure and persistent pulmonary hypertension, and is now a standard

12 ates with hypoxaemic respiratory failure and persistent pulmonary hypertension, but potential adverse

13 neonates transferred for rescue therapy for persistent pulmonary hypertension during the study perio

14 reduced hypoxia-induced vasoconstriction and persistent pulmonary hypertension following recovery fro

15 Infants with persistent pulmonary hypertension have low plasma concen

16 rginine would correlate with the presence of persistent pulmonary hypertension in newborns and that t

17 psis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, and ext

18 psis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, extraco

19 nitric oxide bioactivity in the treatment of persistent pulmonary hypertension of newborns.

20 alpha2 deficiency in smooth muscles promotes persistent pulmonary hypertension of the new-born.

21 idepressant use during pregnancy and risk of persistent pulmonary hypertension of the newborn (PPHN)

22 Severe persistent pulmonary hypertension of the newborn (PPHN)

23 The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN)

24 Infants with persistent pulmonary hypertension of the newborn (PPHN)

25 Persistent pulmonary hypertension of the newborn (PPHN)

26 nary vascular resistance after birth, and in persistent pulmonary hypertension of the newborn (PPHN),

27 e serotonin reuptake inhibitors (SSRIs) with persistent pulmonary hypertension of the newborn (PPHN),

28 nation and clinical outcomes in infants with persistent pulmonary hypertension of the newborn and ass

29 ness of inhaled NO treatment in infants with persistent pulmonary hypertension of the newborn and ass

30 Persistent pulmonary hypertension of the newborn causes

31 Persistent pulmonary hypertension of the newborn is char

32 ression may increase levels of superoxide in persistent pulmonary hypertension of the newborn lung ti

33 Eleven neonates with severe persistent pulmonary hypertension of the newborn receivi

34 ation (ECMO) use or death among infants with persistent pulmonary hypertension of the newborn who rec

35 al unit admission for greater than 48 hours, persistent pulmonary hypertension of the newborn, or mec

36 borns with hypoxemic respiratory failure and persistent pulmonary hypertension of the newborn.

37 anomalies, neonatal withdrawal syndrome, and persistent pulmonary hypertension of the newborn.

38 ions, except for one single-center trial for persistent pulmonary hypertension of the newborn.

39 reliable in identifying patients at risk for persistent pulmonary hypertension or predicting postoper

40 However, persistent pulmonary hypertension (PH) after PEA remains

41 ation fetal lambs, and in newborn lambs with persistent pulmonary hypertension (PPHN) after prenatal

42 led nitric oxide (iNO) in newborn lambs with persistent pulmonary hypertension (PPHN) following prena

43 tion appears to be decreased in infants with persistent pulmonary hypertension (PPHN).

44 In neonates with persistent pulmonary hypertension, therapy with inhaled

45 full-term infants with severe hypoxemia and persistent pulmonary hypertension were randomly assigned

46 In the long-term follow-up he showed persistent pulmonary hypertension which deteriorated des

47 Infection in many cases causes persistent pulmonary hypertension, which impairs gas exc